Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 97
Filter
Add more filters










Publication year range
1.
Acta Naturae ; 13(3): 106-109, 2021.
Article in English | MEDLINE | ID: mdl-34707902

ABSTRACT

Early (preclinical) diagnosis of Parkinson's disease (PD) is a major challenge in modern neuroscience. The objective of this study was to experimentally evaluate a diagnostic challenge test with monoiodotyrosine (MIT), an endogenous inhibitor of tyrosine hydroxylase. Striatal dopamine was shown to decrease by 34% 2 h after subcutaneous injection of 100 mg/kg MIT to intact mice, with the effect not being amplified by a further increase in the MIT dose. The selected MIT dose caused motor impairment in a neurotoxic mouse model of preclinical PD, but not in the controls. This was because MIT reduced striatal dopamine to the threshold of motor symptoms manifestation only in PD mice. Therefore, using the experimental mouse model of preclinical PD, we have shown that a MIT challenge test may be used to detect latent nigrostriatal dysfunction.

2.
Acta Naturae ; 13(3): 110-113, 2021.
Article in English | MEDLINE | ID: mdl-34707903

ABSTRACT

Degeneration of nigrostriatal dopaminergic neurons in Parkinson's disease begins from the axonal terminals in the striatum and, then, in retrograde fashion, progresses to the cell bodies in the substantia nigra. Investigation of the dynamics of axonal terminal degeneration may help in the identification of new targets for neuroprotective treatment and be used as a tool for testing potential drugs. We have shown that the degeneration rate of dopaminergic axonal terminals changes over time, and that the striatal dopamine concentration is the most sensitive parameter to the action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). This model was validated using neuroprotectors with well-known mechanisms of action: the dopamine transporter inhibitor nomifensine and SEMAX peptide that stimulates the secretion of endogenous neurotrophic factors or acts as an antioxidant. Nomifensine was shown to almost completely protect dopaminergic fibers from the toxic effect of MPTP and maintain the striatal dopamine concentration at the control level. However, SEMAX, slightly but reliably, increased striatal dopamine when administered before MPTP treatment, which indicates that it is more effective as an inductor of endogenous neurotrophic factor secretion rather than as an antioxidant.

3.
Acta Naturae ; 13(4): 89-97, 2021.
Article in English | MEDLINE | ID: mdl-35127152

ABSTRACT

According to the literature, the cerebrospinal fluid (CSF) in the cerebral ventricles contains numerous neuron-derived physiologically active substances that can function as neurohormones and contribute to volume neurotransmission in the periventricular region of the brain. This study was aimed at carrying out a comparative analysis of CSF and the blood levels of monoamines in rats during ontogenesis as an indicator of age-related characteristics of monoamine transport to body fluids and their function as neurohormones in volume neurotransmission in the periventricular region of the brain. We have shown that CSF in the perinatal period and adulthood contains the most functionally significant monoamines: dopamine, noradrenaline, and serotonin. A comparison of the monoamine levels in the CSF and blood of animals of different age groups revealed that CSF contains monoamines of predominantly neuronal (cerebral) origin and almost no monoamines derived from the general circulation. We also established that monoamines are found in the CSF at physiologically active levels that allow them to act as neurohormones in both reversible volume neurotransmission in the adult brain and irreversible regulation of brain development in the perinatal period.

4.
Dokl Biochem Biophys ; 493(1): 201-204, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32894465

ABSTRACT

This work is aimed at studying the mechanisms of reciprocal humoral regulation of noradrenaline-producing organs in rats in the perinatal period of development. The activity of noradrenaline synthesis enzymes tyrosine hydroxylase and dopamine-beta-hydroxylase was measured in the brain and adrenal glands 48 and 72 h after the injection of immunotoxin (anti-dopamine-beta-hydroxylase-saporin) into the rat brain ventricles. It was shown that, 48 h after the immunotoxin injection into the brain, the activity of tyrosine hydroxylase in the brain decreased; however, 72 h after the injection it reached the control levels. This fact indicates that noradrenaline synthesis in the survived neurons increases. In the adrenal glands, 72 h after the immunotoxin injection into the brain, the activity of dopamine-beta-hydroxylase increased. This points to a compensatory increase in the rate of noradrenaline synthesis in the adrenal glands when the synthesis of noradrenaline in the brain is inhibited.


Subject(s)
Adrenal Glands/metabolism , Brain/metabolism , Dopamine beta-Hydroxylase/metabolism , Norepinephrine/biosynthesis , Saporins/pharmacology , Tyrosine 3-Monooxygenase/metabolism , Adrenal Glands/drug effects , Animals , Animals, Newborn , Brain/drug effects , Dopamine beta-Hydroxylase/antagonists & inhibitors , Immunotoxins/pharmacology , Male , Rats , Rats, Wistar
5.
Acta Naturae ; 12(2): 52-62, 2020.
Article in English | MEDLINE | ID: mdl-32742727

ABSTRACT

This review provides information on the non-motor peripheral manifestations of Parkinson's disease (PD) associated with a pathology of the visual analyzer and the auxiliary apparatus of the eye. The relationship between neurodegenerative processes that take place in the brain and in the eye opens new prospects to use preventive ophthalmologic examination to diagnose PD long before the characteristic motor symptoms appear. This will encourage the use of neuroprotective therapy, which stops, or at least slows down, neuronal death, instead of the current replacement therapy with dopamine agonists. An important result of an eye examination of patients with PD may be a non-invasive identification of new peripheral biomarkers manifesting themselves as changes in the composition of the lacrimal fluid.

6.
Dokl Biochem Biophys ; 490(1): 34-37, 2020 Jan.
Article in English | MEDLINE | ID: mdl-32342310

ABSTRACT

One of the features of the developing suprachiasmatic nucleus (SCN), the "biological clock" of the body, is the early expression of dopamine (DA) receptors in the absence of dopaminergic neurons as a source of DA. Only recently we showed that DA in SCN is synthesized together by nerve fibers containing only tyrosine hydroxylase (TH) and neurons containing only aromatic L-amino acid decarboxylase (AADC). This study was aimed to assess specific characteristics of the phenotype of TH-fibers in ontogenesis. For this purpose, PCR and immunohistochemical analysis of the expression of genes and proteins such as TH, AADC, vesicular monoamine transporter (VMAT), and receptors for DA (D1, D2) was performed. We have detected numerous TH-immunoreactive fibers in SCN of young and adult rats. VMAT was observed in some of them, which suggests vesicular storage of L-DOPA. Considering the key role of TH-fibers in cooperative synthesis of DA, we assumed the presence of their dopamine regulation. Using double immunolabeling, we showed that D1 and D2 are present in TH-fibers in adult rats, and only D1 in young rats. According to PCR, D1 and D2 are also expressed in neurons of SCN in adult rats and only D1 in young rats. Thus, it was shown for the first time that VMAT and D1 are coexpressed in TH-fibers synthesizing L-DOPA in SCN in young and adult rats, and also D2 receptors in adult rats, which suggests vesicular storage and dopamine regulation of L-DOPA secretion, respectively.


Subject(s)
Aromatic-L-Amino-Acid Decarboxylases/metabolism , Dopamine/metabolism , Neurons/metabolism , Receptors, Dopamine/metabolism , Suprachiasmatic Nucleus/metabolism , Tyrosine 3-Monooxygenase/metabolism , Animals , Dopaminergic Neurons/metabolism , Levodopa/metabolism , Male , Nerve Fibers/metabolism , Phenotype , Rats , Rats, Wistar , Receptors, Dopamine D1/metabolism , Vesicular Monoamine Transport Proteins/metabolism
7.
Article in Russian | MEDLINE | ID: mdl-33459535

ABSTRACT

OBJECTIVE: To determine changes in the chemical composition of blood plasma in subjects at risk of Parkinson's disease (PD) at the prodromal stage compared with age control. MATERIAL AND METHODS: Subjects at risk were selected for the presence of characteristic premotor symptoms, including impairments of sleep, olfaction and constipation.The risk group included 12 people, the control group - 8 people. RESULTS: Among seven catecholamines and their metabolites detected in the blood, only the concentration of L-dioxiphenylalanine (L-DOPA) changed (decreased) in subjects at risk compared with the control. A decrease in the concentration of L-DOPA is considered as a manifestation (marker) of selective degeneration of central and peripheral catecholaminergic neurons in PD. In contrast to L-DOPA, the concentration of seven of the twelve detected sphingomyelins in the blood of the subjects at risk increased. Given that a change in the metabolism of sphingomyelins is associated with processes such as apoptosis, autophagy, and synucleinopathy, an increase in their concentration in the blood of patients at risk is considered as a manifestation of systemic general degeneration of central and peripheral neurons. Finally, in the blood of subjects at risk, we found a trend towards a decrease in the concentration of urates, which are endogenous neuroprotectors. CONCLUSION: The changes in the level of L-DOPA, sphingmyelins and urates in the blood of subjects at risk may serve as diagnostic markers of PD at the prodromal stage.


Subject(s)
Parkinson Disease , Biomarkers , Catecholamines , Early Diagnosis , Humans , Parkinson Disease/diagnosis , Prodromal Symptoms
8.
Dokl Biochem Biophys ; 486(1): 171-174, 2019 May.
Article in English | MEDLINE | ID: mdl-31367814

ABSTRACT

Under conditions of the experimental model of Parkinson's disease at the preclinical (early) and clinical stage-injection of mice with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) for 5 and 10 weeks-the toxic effects of MPTP was evaluated (the content of catecholamines and their metabolites in the heart, which receives the most extensive sympathetic innervation, was determined). The obtained data indicated the beginning of desympathization of the heart at the preclinical stage of PD and its progression at the clinical stage of the disease.


Subject(s)
Catecholamines/metabolism , Neurotoxins/toxicity , Sympathetic Nervous System/drug effects , Sympathetic Nervous System/physiology , Animals , Heart/drug effects , Heart/innervation , Male , Mice , Mice, Inbred C57BL
9.
Dokl Biochem Biophys ; 486(1): 243-246, 2019 May.
Article in English | MEDLINE | ID: mdl-31367831

ABSTRACT

This work represents one part of our research project, in which we attempted to prove that a humoral regulation between noradrenaline-producing organs exist in the perinatal period. In this study, we used a rat model that allowed blocking the synthesis of noradrenalin in the brain and evaluated gene expression and protein levels of noradrenaline key synthesis enzymes such as tyrosine hydroxylase (TH) and dopamine beta-hydroxylase (DBH) in peripheral noradrenaline-producing organs. As a result, we showed an increased gene expression of TH and DBH in adrenal glands. These data indicate that, if neonatal rat brain lacks the ability to produce noradrenaline, then the synthesis of noradrenaline in adrenal glands increased as a compensatory process, so that the concentration levels in blood are maintained at normal levels. This indicates that there is a humoral regulation between brain and adrenal glands, which is not fully understood yet.


Subject(s)
Brain/physiology , Morphogenesis , Norepinephrine/biosynthesis , Animals , Brain/growth & development , Dopamine beta-Hydroxylase/genetics , Gene Expression Regulation, Developmental , Rats , Tyrosine 3-Monooxygenase/genetics
10.
Dokl Biochem Biophys ; 489(1): 373-376, 2019 Nov.
Article in English | MEDLINE | ID: mdl-32130603

ABSTRACT

This work is dedicated to proving our hypothesis that catecholamines and their metabolites play a crucial role in the development of retinopathy of prematurity, which leads to progressive uncontrollable vascularization in the retina, leading to blindness. The study was performed in an animal model of retinopathy of prematurity, which was achieved by hyperoxygenation in rats on postnatal days 7, 14, 21, and 30. The content of catecholamines and their metabolites in the retina of rats was determined by high performance liquid chromatography with electrochemical detection. It was shown that, in the rats with retinopathy, the content of L-DOPA on days 21 and 30 was decreased as compared to the control, whereas the content of noradrenaline on day 14 life increased compared to the control. However, we did not observe changes in the content of dopamine in the experimental animals relative to the control in any period studied. Given the published data on the involvement of catecholamines in the regulation of vasculogenesis in the retina in normal state, our data on the changes in the catecholamine metabolism in the retina in the model of retinopathy of prematurity can be regarded as evidence of the important role of catecholamines in the pathogenesis of this severe disease.


Subject(s)
Catecholamines/metabolism , Retinal Neovascularization/complications , Retinal Neovascularization/metabolism , Retinopathy of Prematurity/complications , Animals , Disease Models, Animal , Rats , Retinal Neovascularization/pathology
11.
Dokl Biochem Biophys ; 489(1): 399-402, 2019 Nov.
Article in English | MEDLINE | ID: mdl-32130610

ABSTRACT

Nigrostriatal dopaminergic neurons (DNs), involved in the regulation of motor function, are characterized by a high plasticity. Indeed, at the death of up to 50% of DNs in Parkinson's disease, the survived neurons provide normal regulation. This study was aimed to determine whether the vesicle cycle proteins, syntaxin Ia (Syn Ia), synaptotagmin I (Syt I), Rab5a, and complexins I and II (Cmpx I and II) are involved in the mechanisms of neuroplasticity in the substantia nigra, which mainly contains cell bodies and processes of the DNs. In the neurotoxic models of Parkinson's disease in mice, it was shown that, at the degeneration of up to 50% of DNs, the content of Syt I, Syn Ia, and Cmpх I and II, involved in vesicle exocytosis, does not change in the substantia nigra as a whole but is compensatorily increased in individual survived DNs. Thus, the data obtained in this study suggest that the impairment of motor behavior, which occurs at the death of half of the nigrostriatal DNs, is not caused by the impairment of the production of vesicle cycle proteins in the survived DNs.


Subject(s)
Dopaminergic Neurons/metabolism , Membrane Proteins/metabolism , Neuronal Plasticity , Substantia Nigra/metabolism , Substantia Nigra/pathology , Animals , Biomarkers/metabolism , Male , Mice , Mice, Inbred C57BL , Parkinson Disease/metabolism , Parkinson Disease/pathology , Parkinson Disease/physiopathology
12.
Acta Naturae ; 11(4): 99-103, 2019.
Article in English | MEDLINE | ID: mdl-31993241

ABSTRACT

An important approach to an early diagnosis of Parkinson's disease (PD) is screening for peripheral biomarkers in patients at the early clinical stage. In this study, we evaluated catecholamine concentration changes in the tear fluid of untreated PD patients as biomarkers. Norepinephrine and dopamine concentrations in the tear fluid of patients were found to increase compared to those in age controls, which was especially pronounced on the side where motor symptoms appeared. On the contrary, the epinephrine concentration in the tear fluid of patients was reduced bilaterally. Since there was no reason to consider the markers found in the clinical stage of PD as markers of the preclinical stage, we additionally studied the tear fluid composition in mouse neurotoxic models of PD preclinical and clinical stages. The norepinephrine concentration in the tear fluid of mice from the clinical stage model was found to be higher than that in controls; in the preclinical stage model, the norepinephrine concentration had a tendency to increase. Therefore, both PD patients and mice from PD preclinical and clinical stage models manifest unidirectional changes in their tear fluid compositions, which may be considered as promising biomarkers for the development of early diagnosis.

13.
Acta Naturae ; 10(3): 62-67, 2018.
Article in English | MEDLINE | ID: mdl-30397528

ABSTRACT

Parkinson's disease (PD) is a systemic neurodegenerative condition caused by the death of dopaminergic neurons of the nigrostriatal system of the brain. This disease is diagnosed after most neurons have already been lost, which explains the low efficiency of treatment. Hope for increasing treatment efficiency rests in the development of new strategies for early diagnosis of PD based on a search for peripheral markers that appear as early changes in non-motor functions. Since impairment of the visual function is one of the manifestations of PD, the purpose of our work was to identify biochemical and physiological changes in a mouse's eye and eyelid in models of preclinical (presymptomatic) and clinical (symptomatic) stages of PD. We found that the norepinephrine, dopamine, and serotonin levels in the mouse eye reduced not only in the model of the early clinical stage, but also in the model of preclinical stage, an indication that pathological changes in the monoaminergic systems of the brain had affected the eye even before the motor disorders emerged. Moreover, in both models of PD, mice had increased intraocular pressure, indicating the development of both metabolic and functional impairments, which can be used as diagnostic markers. Unlike in the eye, the serotonin level in the eyelid was increased in mice at both parkinsonism stages and in presymptomatic mice to a much higher extent than in symptomatic ones. Given that serotonin is involved in the regulation of lacrimal glands of the eyelid, an increase in its level in parkinsonian mice should alter the composition of tear fluid, which could serve as a diagnostic marker of early stage of PD. Thus, the changes in the metabolism of monoamines in the eye and eyelid observed in mice at the early stage of parkinsonism are accompanied by changes in the function of these structures and, therefore, can be used as diagnostic markers of the early stage of PD.

14.
Vestn Oftalmol ; 134(4): 41-46, 2018.
Article in Russian | MEDLINE | ID: mdl-30166509

ABSTRACT

PURPOSE: To estimate the possibility of detection of neurovascular ocular disorders in glaucoma by assessing the content of catecholamines and endothelins in lacrimal fluid. MATERIAL AND METHODS: The study included 47 patients with primary open-angle glaucoma (POAG). Tear eluate was analyzed by high performance liquid chromatography (HPLC) for catecholamines concentrations, and enzyme-linked immunoassay (ELISA) was used for evaluation of endothelins content. RESULTS: Endothelin-1 (ET-1) and big endothelin (bET) content in tears of patients with POAG was higher than in healthy controls. Concentration of dopamine (DA) in tears was lower and concentrations of L-dioxyphenylalanine and dihydroxyphenylacetic acid had a tendency for decrease. Noradrenaline content was equal in patients with POAG and controls. Adrenaline was not detected in any tear samples. CONCLUSION: Multidirectional changes of endothelins and DA levels in tears of patients with POAG was found. The increased concentration of ET-1 and its precursor bET promote vasoconstriction and decrease of aqueous humor outflow. The decrease of DA concentration is typical for neurodegenerative processes. Estimation of DA and endothelins concentrations in tears can enable early detection of neurovascular disorders in glaucoma patients and help evaluate their severity.


Subject(s)
Dopamine , Endothelins , Glaucoma, Open-Angle , Glaucoma , Tears , Aqueous Humor , Dopamine/analysis , Endothelins/analysis , Glaucoma/diagnosis , Humans , Tears/chemistry
15.
Dokl Biochem Biophys ; 479(1): 83-86, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29779103

ABSTRACT

Using an experimental Parkinson's disease model (symptoms develop in mice after the injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), we studied the characteristics of the synthesis of dopamine as a possible compensatory mechanism aimed at maintaining the dopamine level in the dopaminergic neurons that survived in this pathology. We found no correlation between the content and activity of tyrosine hydroxylase in the nigrostriatal system. The enzyme activity and the dopamine content showed unidirectional changes in the substantia nigra, but not in the striatum, which is apparently due to triggering other compensatory mechanisms.


Subject(s)
Dopamine/biosynthesis , Neuronal Plasticity , Substantia Nigra/metabolism , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pharmacology , Animals , Male , Mice , Mice, Inbred C57BL , Neuronal Plasticity/drug effects , Substantia Nigra/drug effects , Substantia Nigra/pathology , Tyrosine 3-Monooxygenase/metabolism
16.
Dokl Biochem Biophys ; 479(1): 123-126, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29779114

ABSTRACT

In the striatum of rats at different stages of development, we determined the content of tyrosine hydroxylase and aromatic L-amino acids decarboxylase using double immunohistochemical labeling and estimated the expression level of their transcripts by real-time PCR. We found that, in different periods of development, there are three sources of dopamine in the striatum of rats: bienzymatic nerve fibers (throughout ontogeny), bienzymatic neurons (appear on day 18 of embryonic development), and monoenzymatic neurons (in adult animals). Dopamine, which is synthesized in the striatal neurons in the prenatal period, may function as a morphogenetic factor.


Subject(s)
Dopamine/metabolism , Neostriatum/growth & development , Neostriatum/metabolism , Animals , Aromatic-L-Amino-Acid Decarboxylases/genetics , Gene Expression Regulation, Enzymologic , Male , Rats , Rats, Wistar , Tyrosine 3-Monooxygenase/genetics
17.
Article in Russian | MEDLINE | ID: mdl-29053133

ABSTRACT

Parkinson's disease is a severe neurodegenerative disease accompanied with the degeneration of dopaminergic neurons in the central and peripheral nervous system. The diagnosis of Parkinson's disease can still be made only on the stage of irreversible and nearly total degeneration of the nigrostriatum dopaminergic system and exhaustion of brain compensatory mechanisms that explains the low efficacy of therapy. Ophthalmic pathology is one of the nonmotor symptoms of Parkinson's disease. This can be explained firstly by the fact that eye is a 'peripheral part of brain' and secondly by the involvement of dopaminergic neurons (dopamine-producing cells) that are subject to the selective degeneration during Parkinson's disease in the regulation of visual function in the eye and brain. Dopaminergic neurons and dopamine receptors are present in all structures of the eye. Parkinson's disease cause abnormalities not only in the retina but in the whole optic tract and can be considered as peripheral manifestations of the disease that precede the well-known motor dysfunctions. This review describes ophthalmological symptoms of Parkinson's disease, possible pathophysiological mechanisms of their development, optical disorders in experimental models of Parkinson's disease and also the perspectives of experimental and clinical studies of visual disorders for the development of preclinical diagnosis of Parkinson's disease.


Subject(s)
Dopaminergic Neurons , Parkinson Disease , Animals , Disease Models, Animal , Dopamine/metabolism , Dopaminergic Neurons/metabolism , Dopaminergic Neurons/pathology , Dopaminergic Neurons/physiology , Eye Diseases/diagnosis , Eye Diseases/pathology , Eye Diseases/physiopathology , Humans , Parkinson Disease/diagnosis , Parkinson Disease/pathology , Parkinson Disease/physiopathology , Receptors, Dopamine/metabolism , Substantia Nigra/pathology
18.
Biomed Khim ; 63(3): 241-247, 2017 May.
Article in Russian | MEDLINE | ID: mdl-28781257

ABSTRACT

A role of nicotinic acetylcholine receptors (nAChR) in the development of Parkinson's disease (PD) has been investigated using two mouse models corresponding to the presymptomatic stage and the early symptomatic stage of PD. Quantitative determination of nAChR in the striatum and substantia nigra (SN) was performed using the radioactive derivatives of epibatidine, -conotoxin MII, and -bungarotoxin as ligands. The number of ligand-binding sites changed differently depending on their location in the brain, the stage of the disease and the receptor subtype. Epibatidine binding decreased in the striatum to 66% and 70% at the presymptomatic and early symptomatic stages, respectively, whereas in SN a 160% increase was registered at the presymptomatic stage. The -conotoxin MII binding on striatal dopaminergic axonal terminals at the presymptomatic stage decreased by 20% and at the symptomatic stage it demonstrated a further decrease. The increase in -bungarotoxin binding at the presymptomatic stage and a decrease at the early symptomatic stage was observed in the striatum. In SN, the level of -bungarotoxin binding decreased at the presymptomatic stage and kept constant at the symptomatic stage. The significant decrease in the expression of Chrna4 and Chrna6 genes encoding 4 and 6 nAChR subunits was observed in SN at the early symptomatic stage, while a 13-fold increase in expression of the Chrna7 gene encoding the 7 nAChR subunit was detected at the presymptomatic stage. The data obtained suggest possible involvement of nAChR in compensatory mechanisms at early PD stages.


Subject(s)
Corpus Striatum/metabolism , Parkinson Disease, Secondary/genetics , Receptors, Nicotinic/genetics , Substantia Nigra/metabolism , alpha7 Nicotinic Acetylcholine Receptor/genetics , Animals , Asymptomatic Diseases , Binding Sites , Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Bungarotoxins/pharmacology , Conotoxins/pharmacology , Corpus Striatum/drug effects , Corpus Striatum/physiopathology , Disease Models, Animal , Disease Progression , Gene Expression Regulation , Humans , Ligands , Mice , Nicotinic Agonists/pharmacology , Organ Specificity , Parkinson Disease, Secondary/metabolism , Parkinson Disease, Secondary/physiopathology , Protein Binding , Protein Isoforms/genetics , Protein Isoforms/metabolism , Pyridines/pharmacology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Nicotinic/metabolism , Signal Transduction , Substantia Nigra/drug effects , Substantia Nigra/physiopathology , alpha7 Nicotinic Acetylcholine Receptor/metabolism
19.
Dokl Biochem Biophys ; 474(1): 200-203, 2017 May.
Article in English | MEDLINE | ID: mdl-28726094

ABSTRACT

Gene expression and content of the key enzymes involved in the synthesis of noradrenaline-tyrosine hydroxylase and dopamine beta-hydroxylase-was evaluated in the organ of Zuckerkandl of rats in the critical period of morphogenesis. High levels of mRNA and protein of both enzymes in the perinatal period of development and their sharp decline on day 30 of postnatal development were detected. These data indicate that the synthesis of noradrenaline in the organ of Zuckerkandl is maximum during the critical period of morphogenesis and decreases during the involution of this paraganglion.


Subject(s)
Dopamine beta-Hydroxylase/metabolism , Gene Expression Regulation, Enzymologic , Morphogenesis , Norepinephrine/biosynthesis , Para-Aortic Bodies/metabolism , Tyrosine 3-Monooxygenase/metabolism , Animals , Dopamine beta-Hydroxylase/genetics , Male , Para-Aortic Bodies/physiology , Rats , Rats, Wistar , Tyrosine 3-Monooxygenase/genetics
20.
Dokl Biochem Biophys ; 472(1): 23-26, 2017 Jan.
Article in English | MEDLINE | ID: mdl-28421436

ABSTRACT

The level of gene expression and the protein content of tyrosine hydroxylase and dopamine ß-hydroxylase were determined. In the perinatal period of rats, when noradrenaline functions as a morphogenetic factor, the level of gene expression of these enzymes increased and the content of protein products of these genes was almost unchanged, indicating the difference in the regulatory mechanisms of their transcription and translation.


Subject(s)
Adrenal Glands/metabolism , Gene Expression Regulation, Developmental , Norepinephrine/metabolism , Adrenal Glands/embryology , Adrenal Glands/enzymology , Animals , Dopamine beta-Hydroxylase/genetics , Dopamine beta-Hydroxylase/metabolism , Male , Organogenesis , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Wistar , Tyrosine 3-Monooxygenase/genetics , Tyrosine 3-Monooxygenase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...